The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAfter years of legal uncertainty, the US Supreme Court delivered a decisive ruling in favor of Bayer, fundamentally altering the trajectory of Roundup cancer lawsuits. The court narrowed the scope of the claims, giving the company a clearer path to resolve thousands of pending cases. Bayer's stock surged 20% following the announcement, according to press reports.
These lawsuits have been a massive legal burden on Bayer since its acquisition of Monsanto in 2018. The ruling is expected to accelerate the settlement of remaining claims. At the close on June 24, Bayer (BAYRY) shares traded at $11.25, up from pre-ruling levels, with a high of $11.39 and a low of $11.17, per market data.
Investors are now watching Bayer's quarterly results due in July, which may reveal the ruling's impact on financial guidance. Markets are also monitoring potential appeals from plaintiffs that could return the case to lower courts. As of the June 24 close, the stock sits at $11.25, with resistance at $11.39 and support at $11.17.